Study of metabolomics as a precision medicine tool (MetCYP)
Research type
Research Study
Full title
Impact of CYP2C9 genotype and CYP2C9 inhibiting drugs on an Individual’s metabolomics and metabolism of tolbutamide for interrogation of drug interactions.
IRAS ID
285840
Contact name
Ewan Pearson
Contact email
Sponsor organisation
University of Dundee
Clinicaltrials.gov Identifier
NA, NA
Duration of Study in the UK
0 years, 10 months, 27 days
Research summary
Medications that are taken by mouth need to get to their site of action (e.g. the liver). They then need to be removed from the body - a combination of metabolism (breakdown of the drug by the body) and elimination (removal of the drug, often in the urine). Most of this drug metabolism is undertaken by a group of chemicals called the CYP enzymes. These CYP enzymes vary between people due to differences in genetics, and also in response to other drugs and a persons diet. The activity of these CYP enzymes can make a big impact on how well a particular drug works, or indeed how likely it is to cause harm.
It would be very helpful to know the status of an individual's CYP enzymes before prescribing a drug as we might choose a higher dose or use one drug in preference of another. The gold standard test to work out how well someone's CYP enzymes are working is a complex and long (>24 hr) study called a pharmacokinetic study. As this is long and complex it is never undertaken before prescribing a drug. If we could develop a simple blood test that can tell us the CYP enzyme activity for an individual we could measure this before prescribing.
In this study we will undertake pharmacokinetic studies to accurately determine activity of one of the CYP enzymes (called CYP2C9). We will do this in people with a particular genetic variant of CYP2C9, and also after they take a tablet that reduces the enzyme activity. We will measure blood chemicals called 'endogenous metabolites' as we have prior evidence that these might give us a snapshot of CYP activity. As proof of principle, we hope to find particular metabolites that are a proxy of CYP2C9 activity.
REC name
West Midlands - Solihull Research Ethics Committee
REC reference
21/WM/0002
Date of REC Opinion
16 Feb 2021
REC opinion
Further Information Favourable Opinion